180976-10-7

Basic information

• Product Name: tert-butyl (2-(((benzyloxy)carbonyl)amino)ethyl)(methyl)carbamate
• Synonyms: tert-butyl (2-(((benzyloxy)carbonyl)amino)ethyl)(methyl)carbamate
• CAS NO: 180976-10-7
• Molecular Weight: 308.378
• Mol File: 180976-10-7.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl (2-(((benzyloxy)carbonyl)amino)ethyl)(methyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (2-(((benzyloxy)carbonyl)amino)ethyl)(methyl)carbamate(180976-10-7)
• EPA Substance Registry System: tert-butyl (2-(((benzyloxy)carbonyl)amino)ethyl)(methyl)carbamate(180976-10-7)

Safety Data

• Hazardous Substances Data: 180976-10-7(Hazardous Substances Data)

Upstream product

• 121492-06-6 (2-aminoethyl)methylcarbamic acid tert-butyl ester 
• 501-53-1 benzyl chloroformate 
• 180976-09-4 cyanomethyl-methyl-carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1026247-25-5 8-[(2-Benzyloxycarbonylamino-ethyl)-methyl-amino]-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid ethyl ester 
• 1027896-00-9 8-[(2-Benzyloxycarbonylamino-ethyl)-methyl-amino]-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid 
• 180976-11-8 benzyl (2-(methylamino)ethyl)carbamate 

Relevant articles and documents

ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to ethyldiamne compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Synthesis and structure-activity relationships of 2-pyridones: A novel series of potent DNA gyrase inhibitors as antibacterial agents

Two novel series of 2-pyridones were synthesized by transposition of the nitrogen of 4-quinolones to the bridgehead position. This subtle interchange of the nitrogen atom with a carbon atom yielded two novel heterocyclic nuclei, pyrido[1,2-a]pyrimidine and quinolizine, which had not previously been evaluated as antibacterial agents and were found to be potent inhibitors of DNA gyrase. Quinolizines with a methyl group at the 9-position such as (S)-45a (ABT-719) demonstrate exceptional broad spectrum antibacterial activity. Most notably, they are active against resistant bacteria such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant strains of enterococci, and ciprofloxacin-resistant organisms. In addition, 2-pyridones also possess favorable physiochemical and pharmacokinetic properties. These 2-pyridones were synthesized from the commercially available starting materials by 10-17 linear transformations. The structure of an adduct yielded by this sequence, (S)-45a (ABT-719), was determined by X-ray crystallographic analysis.